Neopharma Technologies Ltd

Neopharma Technologies Ltd is an Australian public unlisted company that has wholly owned subsidiaries in Malaysia and the USA and has developed a range of industry leading rapid tests and participates in the current $35 Billion (USD) rapid diagnostics market growing to $134 billion (USD) by 2030.

Neopharma aims to be a global leader in the diagnostics market with 16 industry leading and technologically AI integrated products covering Drug Testing, Infectious Disease and Pregnancy. Anchored by its global patented TamperLoks medical device and US trademarked myNEO and NEOVAULT technologies.

All Neopharma products are supported with a fully integrated IT Test Data management platform NEOVAULT, and smartphone apps myNEO and NEOVAULT for the secure collection and recording of test data.

Neopharma will officially launch its recently secured US FDA cleared NEOTEST products and its NEOVAULT ISO 27001, HIPPA and GDPR certified enterprise resource management platform at the SAPAA (Substance Abuse Program Administrators Association) conference in the USA in October 2023.

WHY Neopharma

• Recently received US FDA certification and CE approval for its NEOTEST range.
• Significant product pipeline of approvals to further open up the Australian, European and South East Asian markets with extensive product range.
• A low cost large scale business model.
• Blue sky opportunity to reach $1B + valuation with NEO’s patented technologies and approved test kits paired with NEOVAULT.
• Achieved highest international security and compliance standards with ISO 27001.
• Pipeline of planned audits to achieve GDPR, SOC 2 and HIPPA certifications with a pathway for FedRAMP certification within 6 months.
• myNEOand NEOVAULT app’s approved and now available on the google play and apple stores ready for commercialization.
• NEOVAULT has AI and AR integrated technologies. With ability to sell big data to insurance companies and federal government.
• Australian based Company Headquarters with wholly owned subsidary’sin Malaysia and US ready to scale.
• Significant IP with Global Utility and Design Patents and Registered Trademarks. Neopharma Technologies SbdBhdis ISO 13485 certified.
• After completing company Due Diligence research, Australian Wholesale Investor Market platforms, Onmarket & Venture Crowd have assisted the company raise over $1.5m from professional and sophisticated investors.